Pharmacophore Model Generation of Thrombin Inhibitors


Thrombin, an important factor of clotting system, take part in a variety of physiological actions, such as blood clotting, anticoagulation, thrombosis and fibrinolysis. Inhibiting thrombin is a pivotal and effective step for the prophylaxis of venous and arterial thrombosis, as well as prevent myocardial infarction for high-risk patients. In this study, a three dimensional pharmacophore model was generated for the molecules which are responsible for vasodilation activities targeting thrombin. Ten compounds with known thrombin-inhibiting activity values were selected as training set to generate the hypothesis using GALAHAD program in SYBYL 7.0 software. The best hypothesis comprises five pharmacophore features: four hydrophobes groups and one positively charged group. It has been further validated towards a test set including known activity compounds obtained from Binding Database, the values of effectively active hit A% and comprehensive evaluation index CAI are respectively 63.33% and 2.34, the pharmacophore was proven to be successful in discriminating active and inactive inhibitors.  Furthermore, the pharmacophore model was used as a 3D query to screen TCMD (Version 2009) database and 6 hit compounds of higher predicted activity were the reported cardiovascular activities, which may be useful for further study.

Share and Cite:

X. Wang, Y. Zhang, Y. Xiang, Z. Ren and Y. Qiao, "Pharmacophore Model Generation of Thrombin Inhibitors," Journal of Software Engineering and Applications, Vol. 5 No. 12B, 2012, pp. 84-87. doi: 10.4236/jsea.2012.512B017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Sambrano GR, Weiss EJ, Zheng YW, et al. “Role of thrombin signalling in platelets in haemostasis and thrombosis”. Nature, Vol. 413, No. 6, 2011, pp. 74-78. doi:10.1038/35092573
[2] H LUO, Y LIANG. “Throm-bin-activatable fibrinolysis inhibitor: a new modulator linking coagulation and fibrinolysis”. Basic Medical Sciences and Clinics, Vol. 23, No. 5, 2003, pp. 484-489. doi:6325(2003)05-0484-06
[3] Weitz JI. “Factor Xa and thrombin as targets for new oral anticoagulants”. Thrombosis Research, Vol. 127, No. 2, 2011, pp. S5-S12. doi:10.1016/S0049-3848(10)70147-X
[4] Crawley JT, Zanardelli S, Chion CK, et al. “The central role of thrombin in hemostasis”. Journal of Thrombosis and Haemostasis,Vol. 5, Sup. s1, 2007,pp. 95-101. doi:10.1111/j.1538-7836.2007.02500.x
[5] Nierodzik ML,Karpatkin S. “Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a throm-bin-regulated dormant tumor phenotype”. Cancer Cell, vol.10,No.5,2006, pp.355-362.
[6] Bajzar L, Chan AK, Massicotte MP, et al. “Thrombosis in children with malignancy”. Current Opinion in Pediatrics,vol.18,No.1, 2006 ,pp.1-9. doi:10.1097/01.mop.0000193270.09001.ea
[7] Eriksson BI, Quinlan DJ, Eikelboom JW. “Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Throm-boembolism”. Annual Review of Medicine, vol.62,2011,pp. 41-57. doi:10.1146/annurev-med-062209-095159
[8] Bendel SD, Bona R, Baker WL. “Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation”. Advances in Therapy,vol.28,No.6,2011,pp.460-472. doi:10.1007/s12325-011-0025-1
[9] A. Kobsar , J. Koess-ler , L. Kehrer,etal. “The thrombin inhibitors hirudin and Refludan? activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets”. Thrombo-sisandHaemostasis.Vol.107.No.3,2012,pp.521-529. doi:10.1160/TH11-07-0461
[10] Steinmetzer T, Sturze-becher J. “Progress in the Development of Synthetic Thrombin Inhibitors as New Orally Active Anticoagu-lants”.Current Medicinal Chemistry,Vol.11,No.17, 2004,pp.2297-2321. doi:10.2174/0929867043364540
[11] Santosh P, Gregory A. L., Julie E. P. “Conformation Mining:? An Algorithm for Finding Biologically Relevant Conformations”. J. Med. Chem., Vol. 48, No.9, 2005, pp. 3313-3318. doi:10.1021/jm049066l.
[12] Milan Bruncko, William J. McClellan, Michael D. Wendt, et al. “Naphthamidine urokinase plasminogen activator inhibitors with im-proved pharmacokinetic properties”. Bioorganic & Me-dicinal Chemistry Letters, Vol.15,No.1, 2005, pp. 93-98. doi:10.1016/j.bmcl.2004.10.026
[13] Petra ?tefanic Ander-luh, Marko Anderluh, Janez Ila?. “Toward a Novel Class of Antithrombotic Compounds with Dual Function. Dis-covery of 1,4-Benzoxazin-3(4H)-one Derivatives Pos-sessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic Activities”, J. Med. Chem., 2005, 48 (9), pp 3110–3113. doi:10.1021/jm048984g
[14] Richmond, N.J., Abram, C.A., Wolohan, P.R., et al. “GALAHAD: 1 Pharmacophore Identification by Hypermolecular Alignment of Ligands in 3D”. J COMPUT AID MOL DES, Vol. 20, No. 9, 2006, pp. 567-587. doi:10.1007/s10822-006-9082-y.
[15] N.J. Richmond, P.Willett, R.D. Clark. “Alignment of three-dimensionalmolecules using an image recognition algorithm”. J.Mol.Graph.Model. Vol. 23, No. 2, 2004, pp. 199-209. doi:10.1016/j.bbr.2011.03.031.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.